Internal Medicine, Hematology & Oncology · Easton, MD
NPI
1386641082
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
8221 Teal Dr, Suite 301
Easton, MD, 21601
Phone (410) 820-5945
Groups this clinician bills Medicare through
Medicare paid, 2024
$7.0M
403,580 services
Medicare patients, 2024
1,141
Average age 76
Drug cost, 2024
$10.0M
2,731 prescriptions
Company payments, 2025
$372
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David H Smith was code J1439 (injection, ferric carboxymaltose, 1 mg), 62,250 times for 50 patients. In total David H Smith billed 403,580 services in 174 codes, and Medicare paid $7.0M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-01-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 62,250 | 50 | $0.87 | $54K |
| J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use) | Office | 40,525 | 93 | $2.33 | $94K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 33,405 | 36 | $44.55 | $1.5M |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 22,320 | 16 | $39.09 | $873K |
| J0897 Injection, denosumab, 1 mg | Office | 21,481 | 173 | $20.29 | $436K |
| J0185 Injection, aprepitant, 1 mg | Office | 8,710 | 18 | $1.28 | $11K |
| J1437 Injection, ferric derisomaltose, 10 mg | Office | 8,300 | 76 | $16.28 | $135K |
| Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Office | 5,500 | 15 | $31.54 | $173K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 4,358 | 89 | $0.09 | $385 |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 2,140 | 42 | $0.69 | $1,484 |
| 96375 Injection Administration | Office | 1,160 | 153 | $12.74 | $15K |
| 99213 Office E&M - Established | Office | 1,058 | 616 | $74.77 | $79K |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 784 | 36 | $0.07 | $57.6 |
| 96372 Injection Administration | Office | 723 | 295 | $11.91 | $8,610 |
| 99214 Office E&M - Established | Office | 722 | 354 | $107.40 | $78K |
By year: 2022 $6.7M for 445,527 services; 2023 $9.6M for 645,719 services; 2024 $7.0M for 403,580 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 207 | 159 | $8.65 | $1,791 |
| 85025 Blood Count | 167 | 114 | $7.61 | $1,271 |
| 80053 Clinical Chemistry | 88 | 70 | $10.35 | $911 |
| 82784 Immunoassay | 36 | 11 | $9.11 | $328 |
| 83615 Clinical Chemistry | 28 | 23 | $5.92 | $166 |
| 82728 Clinical Chemistry | 18 | 18 | $13.36 | $240 |
| 82378 Clinical Chemistry | 13 | 11 | $18.58 | $242 |
| 83540 Clinical Chemistry | 12 | 12 | $6.34 | $76.08 |
| 84466 Clinical Chemistry | 12 | 12 | $12.50 | $150 |
Medicare prescription drug claims, 2024
In 2024, the drug David H Smith prescribed most often to Medicare patients was Eliquis (Apixaban), with 326 prescriptions and refills. In total David H Smith wrote 2,731 Medicare prescriptions that cost $10.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 326 | 395 | 58 | $224K |
| Prednisone Generic | 194 | 205 | 57 | $1,166 |
| Anastrozole Generic | 152 | 354 | 44 | $3,030 |
| Xarelto Rivaroxaban | 135 | 191 | 23 | $100K |
| Hydroxyurea Generic | 117 | 206 | 25 | $2,544 |
| Tamoxifen Citrate Generic | 106 | 210 | 26 | $2,261 |
| Abiraterone Acetate Generic | 88 | 99 | 17 | $168K |
| Dexamethasone Generic | 87 | 124 | 30 | $1,129 |
| Ondansetron Hcl Generic | 72 | 72 | 45 | $562 |
| Jakafi Ruxolitinib Phosphate | 71 | 71 | Under 11 | $1.2M |
| Gabapentin Generic | 64 | 94 | 16 | $766 |
| Acyclovir Generic | 63 | 81 | 14 | $905 |
| Pomalyst Pomalidomide | 61 | 61 | Under 11 | $1.3M |
| Imbruvica Ibrutinib | 52 | 52 | Under 11 | $772K |
| Revlimid Lenalidomide | 52 | 52 | Under 11 | $874K |
Brand drugs: 1,076 claims; generic drugs: 1,655 claims; opioid claims: 45.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David H Smith $372 ($372 in general payments such as food, travel and fees) from 8 companies. The largest payer was Gilead Sciences, Inc. with $123.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.